

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



18 December 2025

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

**Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – US FDA determines Baska facility inspection classification as OAI**

This is to inform that the US FDA conducted an inspection at the Company's Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI).

We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status.

**For Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983